肾脏病与透析肾移植杂志 ›› 2016, Vol. 25 ›› Issue (1): 77-81.DOI: 10.3969/cndt.j.issn.1006-298X.2016.01.017
• 论文 • 上一篇 下一篇
出版日期:
发布日期:
Online:
Published:
摘要：
终末期肾病（ESRD）患者合并心血管疾病发生率高。阻断醛固酮受体在降血压的同时还具有逆转心室重构的作用，因此醛固酮受体拮抗剂（MRA）可降低心血管事件的风险。最近研究发现尽管少部分患者存在肾功能受损和轻度高钾血症，MRA仍可改善ESRD患者的预后。
关键词: 终末期肾病, 醛固酮受体拮抗剂, 高钾血症, 心血管事件
Abstract:
Most patients with end-stage renal disease (ESRD) suffer from cardiovascular disease. Treatment with mineralocorticoid receptor antagonists (MRAs) reduce cardiac risk effectively. MRAs not only have the potential to reduce blood pressure but also to promote favorable remodeling of cardiac ventricle. Recent researches have suggested that MRAs can improve survival in ESRD patients, though few parts of patients have the risks of hyperkalemia and reduced renal function. In this review, we highlight the potential cardiovascular benefits and review the evident risks of MRAs in ESRD patients.
李喆,谢红浪. 终末期肾病患者醛固酮受体拮抗剂的应用[J]. 肾脏病与透析肾移植杂志, 2016, 25(1): 77-81.
LI Zhe,XIE Honglang. Aldosterone receptor antagonists in endstage renal disease patients[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2016, 25(1): 77-81.
0 / / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: http://www.njcndt.com/CN/10.3969/cndt.j.issn.1006-298X.2016.01.017
http://www.njcndt.com/CN/Y2016/V25/I1/77
